This mechanism is supported by evidence from Ghiringhelli et al. [43] showing that breast cancer patients treated with adjuvant chemotherapy develop more aggressive metastatic disease if carrying the P2RX7 mutation E496A, which abrogates pore function. Here, P2RX7 is linked to breast carcinoma.